Sign up to save your podcasts
Or
Share JAMA Oncology : Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
JAMA Oncology : Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer
Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
View all episodes
By The JAMA Network
4.9
1212 ratings
Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
More shows like JAMA Network
View all
JAMA Editors' Summary
129 Listeners
Neurology® Podcast
285 Listeners
NEJM This Week
314 Listeners
JAMA Author Interviews
162 Listeners
Diabetes Core Update
97 Listeners
Practical Neurology Podcast
44 Listeners
JAMA Clinical Reviews
488 Listeners
Mayo Clinic Talks
269 Listeners
JAMA Cardiology Author Interviews
9 Listeners
JAMA Dermatology Author Interviews
17 Listeners
JAMA Internal Medicine Author Interviews
19 Listeners
JAMA Psychiatry Author Interviews
22 Listeners
JAMA Medical News
83 Listeners
Core IM | Internal Medicine Podcast
1,090 Listeners
Psychiatry & Psychotherapy Podcast
1,319 Listeners
JAMAevidence The Rational Clinical Examination
29 Listeners
Annals On Call Podcast
184 Listeners
The Clinical Problem Solvers
508 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
321 Listeners
JAMAevidence JAMA Guide to Statistics and Methods
19 Listeners
The Curious Clinicians
362 Listeners
AMA Update
99 Listeners